Repros Therapeutics (RPRX) Submits MAA for Enclomiphene to EMA as Secondary Hypogonadism Treatment
Go back to Repros Therapeutics (RPRX) Submits MAA for Enclomiphene to EMA as Secondary Hypogonadism Treatment| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 27.98 +0.16 (0.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.82 | 52 Week High | $3.48 | |||
| Open | $27.90 | 52 Week Low | $0.80 | |||
| Day High | $28.00 | P/E | N/A | |||
| Day Low | $27.60 | EPS | $-1.54 | |||
| Volume | 2,578,317 | |||||
